navan
/
Daily-Dose
mirror of https://github.com/navanchauhan/Daily-Dose.git
1
0
Fork 0
Code Issues Projects Releases Wiki Activity

Added daily report

This commit is contained in:
Navan Chauhan 2021-10-08 12:49:09 +00:00
parent 20f0454e1c
commit 064312665d
3 changed files with 714 additions and 2 deletions
Show Stats Download Patch File Download Diff File Expand all files Collapse all files

204
archive-covid-19/08 October, 2021.html Normal file
View File

@ -0,0 +1,204 @@
<!DOCTYPE html>
<html lang="" xml:lang="" xmlns="http://www.w3.org/1999/xhtml"><head>
<meta charset="utf-8"/>
<meta content="pandoc" name="generator"/>
<meta content="width=device-width, initial-scale=1.0, user-scalable=yes" name="viewport"/>
<title>08 October, 2021</title>
<style type="text/css">
code{white-space: pre-wrap;}
span.smallcaps{font-variant: small-caps;}
span.underline{text-decoration: underline;}
div.column{display: inline-block; vertical-align: top; width: 50%;}
</style>
<title>Covid-19 Sentry</title><meta content="width=device-width, initial-scale=1.0" name="viewport"/><link href="styles/simple.css" rel="stylesheet"/><link href="../styles/simple.css" rel="stylesheet"/><link href="https://unpkg.com/aos@2.3.1/dist/aos.css" rel="stylesheet"/><script src="https://unpkg.com/aos@2.3.1/dist/aos.js"></script></head>
<body>
<h1 data-aos="fade-down" id="covid-19-sentry">Covid-19 Sentry</h1>
<h1 data-aos="fade-right" data-aos-anchor-placement="top-bottom" id="contents">Contents</h1>
<ul>
<li><a href="#from-preprints">From Preprints</a></li>
<li><a href="#from-clinical-trials">From Clinical Trials</a></li>
<li><a href="#from-pubmed">From PubMed</a></li>
<li><a href="#from-patent-search">From Patent Search</a></li>
</ul>
<h1 data-aos="fade-right" id="from-preprints">From Preprints</h1>
<ul>
<li><strong>How the COVID-19 pandemic impacted the perception of climate change in the UK</strong> -
<div>
Forthcoming in American Behavioral Scientist (ABS) The COVID-19 pandemic erupted during the climate change (CC) crisis, forcing individuals to adapt abruptly to a new scenario, and triggering changes in everyone’s lifestyles. Based on a representative sample of the UK population (N= 1013) this paper investigates how the COVID-19 pandemic invited/forced individuals to reflect upon a new sustainable way of life and to (re)consider the anthropogenic impact on the environment. The results show that age and education are negatively associated with skepticism relating to the human impact on CC, while other control variables such as income, gender and employment status, have a limited impact on this attitude toward CC. Secondly, findings indicate a clear separation between those with a minimal standard of education, who support the natural origin of CC, while individuals with a higher level of education believe that CC is caused by human actions. Finally, on average, younger and more educated individuals tend to associate the COVID-19 pandemic with an opportunity to promote an eco-friendly world and to adopt an eco-sustainable approach.
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://osf.io/46szu/" target="_blank">How the COVID-19 pandemic impacted the perception of climate change in the UK</a>
</div></li>
<li><strong>Psychopathology and Perceived Discrimination Among Chinese International Students One Year into COVID-19: A Preregistered Comparative Study</strong> -
<div>
Background and Objectives: During the COVID-19 pandemic, Chinese international students (CISs) experienced increased distress associated with a combination of unique and universal stressors, among which discrimination against Chinese is especially harmful. Therefore, studying correlates of distress among CISs, including the association between discrimination and distress and factors intensifying or attenuating this link, may yield important insights into prevention and intervention efforts. Design: We adopted a cross-sectional self-report design. Methods: Our study compared depression and anxiety between CISs (N = 381) and Chinese students in Chinese colleges (CSCCs; N = 306) and examined correlates of distress including the association between discrimination and distress as well as moderators on this link within CISs. Results: Compared to CSCCs, CISs reported greater depression and anxiety. Depression was associated with being female, older, non-heterosexual, increased discrimination, decreased self- esteem, coping flexibility, perceived social support, and satisfaction with online learning. Anxiety was associated with being female, heterosexual, in undergraduate years, increased discrimination, decreased self-esteem, subjective socioeconomic status, coping flexibility, and satisfaction with online learning. High perceived social support and being heterosexual weakened the association between discrimination and distress (anxiety and depression). Conclusions: Our study underscored the impact of the pandemic and related discrimination on CISs and highlighted individual differences that may warrant attention.
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://psyarxiv.com/mtk7w/" target="_blank">Psychopathology and Perceived Discrimination Among Chinese International Students One Year into COVID-19: A Preregistered Comparative Study</a>
</div></li>
<li><strong>Genomic Surveillance in Japan of AY.29—A New Sub-lineage of SARS-CoV-2 Delta Variant with C5239T and T5514C Mutations</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
In the present study, we report a new sub-lineage of the SARS-CoV-2 Delta variant called AY.29, which has C5239T and T5514C mutations. We investigated the monthly trend of AY.29 in Japan within 37,737 Delta variants downloaded on October 2, 2021. Among the total Japanese Delta variants, the AY.29 sub-lineage accounted for 95.1%. In terms of monthly trends, the sequences became predominant in June, and accounted for 95.4%, 97.6% and 90.5% of the reported sequences in July, August and September, respectively. Furthermore, the number of Delta variants imported from abroad during the Tokyo 2020 Olympics and Paralympics (held in August 2021) was extremely low during the fifth wave in Japan. Therefore, the epidemic of the new Delta variant is attributable to a newly occurring mutation in Japan.
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.09.20.21263869v3" target="_blank">Genomic Surveillance in Japan of AY.29—A New Sub-lineage of SARS-CoV-2 Delta Variant with C5239T and T5514C Mutations</a>
</div></li>
<li><strong>The COVID States Project #64: Continued high public support for mandating vaccines</strong> -
<div>
COVID-19 continues to surge in the United States and elsewhere, propelled by the highly contagious Delta variant. As of this writing (on September 29, 2021), about three quarters (76%) of the eligible U.S. population (age 12 and up) have received at least one dose of a COVID-19 vaccine. This is likely not enough to achieve herd immunity in the United States. Though the specific number remains uncertain, a recent estimate by the Infectious Diseases Society of America suggests that over 80% of the entire population must be fully vaccinated to reach herd immunity. More worrisome, around 1 in 5 Americans, depending on the poll, continue to say they are either uncertain or will not get the vaccine. In our most recent survey wave (fielded from August 26 to September 27, 2021), 10% of respondents who indicated that they are not yet vaccinated claimed they are extremely unlikely to get it. Another 12% are “somewhat” unlikely to seek the vaccine. In recent weeks, the Biden administration has shifted tactics in its efforts to get as many Americans as possible vaccinated. The Administration had from the outset emphasized the benefits of getting vaccinated as its primary strategy for persuading reluctant Americans to do so. Yet, starting in September the prevailing strategy seemingly shifted from emphasizing carrots to sticks. On September 9th, President Biden issued an executive order requiring all federal employees and government contractors to be vaccinated, and also announced that the U.S. Department of Labor would require that all companies with more than 100 employees require vaccination or weekly testing, as well as provide paid time off for employees to get vaccinated. The Biden Administration has also encouraged states and smaller companies to impose similar vaccine mandates. The question arises as to whether the persistence of the Delta variant has increased public support for making COVID-19 vaccines mandatory. In our April/May survey wave, six in ten respondents approved of the government mandating vaccines for everyone (see Report #52). This figure increased modestly, to 64% in our June/July survey (see Report #58). In this report, we update our assessment of public support for vaccine mandates, both nationally and across the 50 states, based on our September survey wave.
</div>
<div class="article-link article- html-link">
🖺 Full Text HTML: <a href="https://osf.io/9ac3d/" target="_blank">The COVID States Project #64: Continued high public support for mandating vaccines</a>
</div></li>
<li><strong>Giving a Socially Distanced Voice to Disabled Young People: Insights from the Educational Pathways and Work Outcomes Qualitative Longitudinal Study</strong> -
<div>
The COVID-19 pandemic has created unprecedented challenges for social research. However, little is known about the impact of social distancing measures on research with hard-to-reach populations. This paper provides a methodological reflection on the efficiency of socially distanced recruitment and interviewing methods for research with disabled young people, drawing on our experience from the Educational Pathways and Work Outcomes longitudinal study, which started in November 2020 during the second national lockdown in England. We discuss difficulties in gaining access to disabled young people and argue that the pandemic has exacerbated longstanding barriers implicated in the recruitment of hard-to- reach populations who are typically seen as vulnerable by gatekeepers. In contrast, our experience suggests that flexible online/virtual interviews can overcome pitfalls inherent in the face-to-face interviewing of disabled young people and could therefore be utilised to make their voices heard in a variety of contexts and scenarios beyond the ongoing pandemic.
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://osf.io/preprints/socarxiv/ps367/" target="_blank">Giving a Socially Distanced Voice to Disabled Young People: Insights from the Educational Pathways and Work Outcomes Qualitative Longitudinal Study</a>
</div></li>
<li><strong>High-throughput Activity Assay for Screening Inhibitors of the SARS-CoV-2 Mac1 Macrodomain</strong> -
<div>
Macrodomains are a class of conserved ADP-ribosylhydrolases expressed by viruses of pandemic concern, including coronaviruses and alphaviruses. Viral macrodomains are critical for replication and virus-induced pathogenesis; therefore, these enzymes are a promising target for antiviral therapy. However, no potent or selective viral macrodo- main inhibitors currently exist, in part due to the lack of a high-throughput assay for this class of enzymes. Here, we developed a high-throughput ADP-ribosylhydrolase assay using the SARS-CoV-2 macrodomain Mac1. We performed a pilot screen which identified dasatinib and dihydralazine as ADP-ribosylhydrolase inhibitors. Importantly, dasatinib does not inhibit MacroD2, the closest Mac1 homolog in humans. Our study demonstrates the feasibility of identifying selective inhibitors based on ADP-ribosylhydrolase activity, paving the way for screening large compound libraries to identify improved macrodomain inhibitors and explore their potential as antiviral therapies for SARS-CoV-2 and future viral threats.
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.biorxiv.org/content/10.1101/2021.10.07.463234v1" target="_blank">High-throughput Activity Assay for Screening Inhibitors of the SARS-CoV-2 Mac1 Macrodomain</a>
</div></li>
<li><strong>Measuring host immune response status by simultaneous quantitative measurement of activity of signal transduction pathways that coordinate functional activity of immune cells from innate and adaptive immune system</strong> -
<div>
Abstract For many diseases, including cancer, viral infections such as COVID-19, bacterial infections, and auto- immune diseases, the immune response is a major determinant of progression, response to therapy, and clinical outcome. Innate and adaptive immune response are controlled by coordinated activity of multiple immune cell types. The functional activity state of immune cells is determined by cellular signal transduction pathways (STPs). A novel mRNA-based signaling pathway assay platform has been developed to quantitatively measure relevant STP activities in all types of immune cells and mixed immune cell samples for experimental and diagnostic purposes. We generated a STP activity profile, termed Immune-Pathway Activity Profile (I-PAP), for a variety of immune cell types in resting and activated state, and provide a first example for use in patient samples. Methods. The technology to measure STP activity has been described for androgen and estrogen receptor, PI3K, MAPK, TGFB;, Notch, NFkB, JAK-STAT1/2, and JAK-STAT3 pathways. STP activity was measured on Affymetrix expression microarray data from preclinical studies containing public data from different types of immune cells, resting/naive or immune-activated in vitro, to establish I-PAPs. Subsequently data from a clinical study on rheumatoid arthritis were analyzed. Results. I-PAPs of naive/resting and immune-activated CD4+ and CD8+ T cells, T helper cells, B cells, NK cells, monocytes, macrophages, and dendritic cells were established and in agreement with known experimental immunobiology. In whole blood samples of rheumatoid arthritis patients TGF{beta} pathway activity was increased; JAK-STAT3 pathway activity was selectively increased in female patients. In naive CD4+ Tregs TGFB; pathway activity was increased, while in memory T effector cells JAK-STAT3 pathway activity tended to increase, suggesting that these immune cell types contributed to whole blood analysis results. Conclusion. STP assay technology (currently being converted to qPCR-based assays) makes it possible to directly measure functional activity of cells of the innate and adaptive immune response enabling quantitative assessment of the immune response of an individual patient. Envisioned utility lies in (1) prediction and monitoring of response to immunomodulatory treatments for a variety of immune-mediated diseases, including RA; (2) uncovering novel treatment targets; (3) improvement and standardization of in vitro immunology research and drug development.
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.biorxiv.org/content/10.1101/2021.10.06.463309v1" target="_blank">Measuring host immune response status by simultaneous quantitative measurement of activity of signal transduction pathways that coordinate functional activity of immune cells from innate and adaptive immune system</a>
</div></li>
<li><strong>TITLE: Randomised Controlled Trial of Intravenous Nafamostat Mesylate in COVID pneumonitis: Phase 1b/2a Experimental Study to Investigate Safety, Pharmacokinetics and Pharmacodynamics</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Despite the success of vaccines and selected repurposed treatments, COVID-19 is likely to remain a global health problem and further chemotherapeutics are required. Many repurposed drugs have progressed rapidly to Phase 2 and 3 trials without characterisation of Pharmacokinetics (PK)/Pharmacodynamics (PD) including safety in COVID-19. One such drug is Nafamostat Mesylate (Nafamostat), a synthetic serine protease inhibitor with anticoagulant and anti-inflammatory properties. Preclinical data has demonstrated that it is has potent antiviral activity against SARS-CoV-2 by directly inhibiting the transmembrane protease serine 2 (TMPRSS2) dependent stage of host cell entry. Methods: We present the findings of a phase Ib/II open label, platform randomised controlled trial (RCT), exploring the safety of intravenous Nafamostat in hospitalised patients with confirmed COVID-19 pneumonitis. Patients were assigned randomly to standard of care (SoC), Nafamostat or an alternative therapy. Secondary endpoints included clinical endpoints such as number of oxygen free days and clinical improvement/ deterioration, PK/PD, thromboelastometry, D Dimers, cytokines, immune cell flow cytometry and viral load. Results: Data is reported from 42 patients, 21 of which were randomly assigned to receive intravenous Nafamostat. The Nafamostat group developed significantly higher plasma creatinine levels, more adverse events and a lower number of oxygen free days. There were no other statistically significant differences in the primary or secondary endpoints between Nafamostat and SoC. PK data demonstrated that intravenous Nafamostat was rapidly broken down to inactive metabolites. We observed an antifibrinolytic profile, and no significant anticoagulant effects in thromboelastometry. Participants in the Nafamostat group had higher D Dimers compared to SoC. There were no differences in cytokine profile and immune cell phenotype and viral loads between the groups. Conclusion In hospitalised patients with COVID-19, we did not observe evidence of anti-inflammatory, anticoagulant or antiviral activity with intravenous Nafamostat. Given the number of negative trials with repurposed drugs, our experimental medicine trial highlights the value of PK/PD studies prior to selecting drugs for efficacy trials. Given the mechanism of action, further evaluation of Nafamostat delivered via a different route may be warranted. This trial demonstrates the importance of experimental trials in new disease entities such as COVID-19 prior to selecting drugs for larger trials.
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.10.06.21264648v1" target="_blank">TITLE: Randomised Controlled Trial of Intravenous Nafamostat Mesylate in COVID pneumonitis: Phase 1b/2a Experimental Study to Investigate Safety, Pharmacokinetics and Pharmacodynamics</a>
</div></li>
<li><strong>Monitoring sociodemographic inequality in COVID-19 vaccination coverage in England: a national linked data study</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Background: The UK began an ambitious COVID-19 vaccination programme on 8th December 2020. This study describes variation in vaccination coverage by sociodemographic characteristics between December 2020 and August 2021. Methods: Using population-level administrative records linked to the 2011 Census, we estimated monthly first dose vaccination rates by age group and sociodemographic characteristics amongst adults aged 18 years or over in England. We also present a tool to display the results interactively. Findings: Our study population included 35,223,466 adults. A lower percentage of males than females were vaccinated in the young and middle age groups (18-59 years) but not in the older age groups. Vaccination rates were highest among individuals of White British and Indian ethnic backgrounds and lowest among Black Africans (aged ≥80 years) and Black Caribbeans (18-79 years). Differences by ethnic group emerged as soon as vaccination roll-out commenced and widened over time. Vaccination rates were also lower among individuals who identified as Muslim, lived in more deprived areas, reported having a disability, did not speak English as their main language, lived in rented housing, belonged to a lower socio-economic group, and had fewer qualifications. Interpretation: We found inequalities in COVID-19 vaccination rates by sex, ethnicity, religion, area deprivation, disability status, English language proficiency, socio-economic position, and educational attainment, but some of these differences varied by age group. Research is urgently needed to understand why these inequalities exist and how they can be addressed.
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.10.07.21264681v1" target="_blank">Monitoring sociodemographic inequality in COVID-19 vaccination coverage in England: a national linked data study</a>
</div></li>
<li><strong>Protection Across Age Groups of BNT162b2 Vaccine Booster against Covid-19</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
BACKGROUND Following administration to persons 60+ years of age, the booster vaccination campaign in Israel was gradually expanded to younger age groups who received a second dose &gt;5 months earlier. We study the booster effect on COVID-19 outcomes. METHODS We extracted data for the period July 30, 2021 to October 5, 2021 from the Israeli Ministry of Health database regarding 4,616,994 persons. We compared confirmed Covid-19 infections, severe illness, and death of those who received a booster ≥12 days earlier (booster group) with a nonbooster group. In a secondary analysis, we compared the rates 3-7 days with ≥12 days after receiving the booster dose. We used Poisson regressions to estimate rate ratios after adjusting for possible confounding factors. RESULTS Confirmed infection rates were ≈10-fold lower in the booster versus nonbooster group (ranging 8.8-17.8 across five age groups) and 4.7-11.4 fold lower in the secondary analysis. Severe illness rates in the primary and secondary analysis were 19.1-fold (95% CI, 15.9-23) and 6.5-fold (95% CI, 5.1-8.4) lower for ages 60+, and 20.7-fold (95% CI, 9.7-44.2) and 2.9-fold (95% CI, 1-8.8) lower for ages 40-60. For ages 60+, COVID-19 associated death rates were 13.9-fold (95% CI, 8.8-22) lower in the primary analysis and 4.6-fold (95% CI, 2.7-7.9) lower in the secondary analysis. CONCLUSIONS Across all age groups, rates of confirmed infection and severe illness were substantially lower among those who received a booster dose of the BNT162b2 vaccine.
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.10.07.21264626v1" target="_blank">Protection Across Age Groups of BNT162b2 Vaccine Booster against Covid-19</a>
</div></li>
<li><strong>Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein after infection and/or vaccination</strong> -
<div>
Background: Control of the COVID-19 pandemic will rely on SARS-CoV-2 vaccine-elicited antibodies to protect against emerging and future variants; an understanding of the unique features of the humoral responses to infection and vaccination, including different vaccine platforms, is needed to achieve this goal. Methods: The epitopes and pathways of escape for Spike-specific antibodies in individuals with diverse infection and vaccination history were profiled using Phage-DMS. Principal component analysis was performed to identify regions of antibody binding along the Spike protein that differentiate the samples from one another. Within these epitope regions we determined potential escape mutations by comparing antibody binding of peptides containing wildtype residues versus peptides containing a mutant residue. Results: Individuals with mild infection had antibodies that bound to epitopes in the S2 subunit within the fusion peptide and heptad-repeat regions, whereas vaccinated individuals had antibodies that additionally bound to epitopes in the N- and C-terminal domains of the S1 subunit, a pattern that was also observed in individuals with severe disease due to infection. Epitope binding appeared to change over time after vaccination, but other covariates such as mRNA vaccine dose, mRNA vaccine type, and age did not affect antibody binding to these epitopes. Vaccination induced a relatively uniform escape profile across individuals for some epitopes, whereas there was much more variation in escape pathways in in mildly infected individuals. In the case of antibodies targeting the fusion peptide region, which was a common response to both infection and vaccination, the escape profile after infection was not altered by subsequent vaccination. Conclusions: The finding that SARS-CoV-2 mRNA vaccination resulted in binding to additional epitopes beyond what was seen after infection suggests protection could vary depending on the route of exposure to Spike antigen. The relatively conserved escape pathways to vaccine-induced antibodies relative to infection-induced antibodies suggests that if escape variants emerge, they may be readily selected for across vaccinated individuals. Given that the majority of people will be first exposed to Spike via vaccination and not infection, this work has implications for predicting the selection of immune escape variants at a population level. Funding: This work was supported by NIH grants AI138709 (PI Overbaugh) and AI146028 (PI Matsen). Julie Overbaugh received support as the Endowed Chair for Graduate Education (FHCRC). The research of Frederick Matsen was supported in part by a Faculty Scholar grant from the Howard Hughes Medical Institute and the Simons Foundation. Scientific Computing Infrastructure at Fred Hutch was funded by ORIP grant S10OD028685.
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.biorxiv.org/content/10.1101/2021.10.05.463210v1" target="_blank">Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein after infection and/or vaccination</a>
</div></li>
<li><strong>Adverse events following COVID-19 vaccination in young Japanese people: A case-control study of the risk of systemic adverse events by a questionnaire survey Short title: COVID-19 vaccine adverse events in young Japanese</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
What is known and objective Racial differences in adverse events following COVID-19 vaccines have not been sufficiently studied. Here, we aimed to study the adverse events of Moderna9s intramuscular COVID-19 vaccine in young Japanese people. Methods A case-control study was conducted using a questionnaire survey. Risk factors were determined using a multivariable logistic regression model. We also compared the occurrence of systemic adverse events in three pairs (minor and adult; male and female; and occurrence and non-occurrence of adverse events after the first dose). Propensity matching was used to balance variables. Results We analysed 3,369 data points (1,877 after the first dose and 1,492 after the second dose) obtained from a questionnaire survey of 7,965 vaccinated individuals. Comparing the results of the first and second doses, the incidence of local adverse events did not change significantly; however, the incidence of systemic adverse events increased significantly (p &lt; 0.001). Eighty-three percent of the participants complained of local adverse events, and 65% of participants complained of systemic adverse events. Anaphylaxis occurred in one female student (0.03%). Even when an adverse event occurred, most of the symptoms improved within 3 days. Female sex was associated with systemic adverse events after the first and second doses with odds ratios (ORs) (95% confidence interval, CI) of 2.49 (2.03-3.06), and 1.83 (1.28-2.61), respectively. Age (&lt;20 years: minor) was associated with systemic adverse events after the first dose with an OR of 1.80 (1.44-2.24). The results of the analysis of six cohorts that were created using propensity score matching showed that the incidence of systemic adverse events at the first dose in females was significantly higher than that in males, and that of minors was significantly higher than that of adults. What is new and conclusion The results of this study clarified, for the first time, the risk factors for several adverse events from the injection of Moderna9s intramuscular COVID-19 vaccine in young Japanese people. This study suggests that women, minors who experienced adverse events after the first dose, those who experienced adverse events after the first dose, and those who had adverse events after the second dose, should be aware of adverse events.
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.10.01.21264393v2" target="_blank">Adverse events following COVID-19 vaccination in young Japanese people: A case-control study of the risk of systemic adverse events by a questionnaire survey Short title: COVID-19 vaccine adverse events in young Japanese</a>
</div></li>
<li><strong>Fourteen-days Evolution of COVID-19 Symptoms During the Third Wave in Non-vaccinated Subjects and Effects of Hesperidin Therapy: A randomized, double-blinded, placebo-controlled study.</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
COVID-19 symptoms can cause substantial disability, yet no therapy can currently reduce their frequency or duration. We conducted a double-blind placebo-controlled trial of hesperidin 1000 mg once-daily for 14 days in 216 symptomatic non-vaccinated COVID-19 subjects. Thirteen symptoms were recorded after 3, 7, 10 and 14 days. The primary endpoint was the proportion of subjects with any of four cardinal (group A) symptoms: fever, cough, shortness of breath or anosmia. At baseline, symptoms in decreasing frequency were: cough (53.2%), weakness (44.9%), headache (42.6%), pain (35.2%), sore throat (28.7%), runny nose (26.9%), chills (22.7%), shortness of breath (22.2%), anosmia (18.5%), fever (16.2%), diarrhea (6.9%), nausea/vomiting (6.5%) and irritability/confusion (3.2%). Group A symptoms in the placebo vs hesperidin group was 88.8% vs 88.5% (day 1) and reduced to 58.5 vs 49.4 % at day 14 (OR 0.69, 95% CI 0.38–1.27, p = 0.23). At day 14, 15 subjects in the placebo group and 28 in the hesperidin group failed to report their symptoms. In an attrition bias analysis imputing ″no symptoms″ to missing values, the hesperidin group shows reduction of 14.5 % of group A symptoms from 50.9% to 36.4% (OR: 0.55, 0.32–0.96, p = 0.03). Anosmia, the most frequent persisting symptom (29.3%), was lowered by 7.3% at 25.3 % in the hesperidin group vs 32.6% in the placebo group (p = 0.29). Mean number of symptoms in placebo and hesperidin was 5.10 ± 2.26 vs 5.48 ± 2.35 (day 1) and 1.40 ± 1.65 vs 1.38 ± 1.76 (day 14) (p = 0.92). In conclusion, most non-vaccinated COVID-19 infected subjects remain symptomatic after 14 days with anosmia being the most frequently persisting symptom. Hesperidin 1g daily may help reduce group A symptoms. Earlier treatment of longer duration and/or higher dosage should be tested.
</p>
</div>
<div class="article-link article-html- link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.10.04.21264483v2" target="_blank">Fourteen-days Evolution of COVID-19 Symptoms During the Third Wave in Non-vaccinated Subjects and Effects of Hesperidin Therapy: A randomized, double-blinded, placebo-controlled study.</a>
</div></li>
<li><strong>The translational landscape of SARS-CoV-2 and infected cells</strong> -
<div>
SARS-CoV-2 utilizes a number of strategies to modulate viral and host mRNA translation. Here, we used ribosome profiling in SARS-CoV-2 infected model cell lines and primary airway cells grown at the air-liquid interface to gain a deeper understanding of the translationally regulated events in response to virus replication. We find that SARS-CoV-2 mRNAs dominate the cellular mRNA pool but are not more efficiently translated than cellular mRNAs. SARS-CoV-2 utilized a highly efficient ribosomal frameshifting strategy in comparison to HIV-1, suggesting utilization of distinct structural elements. In the highly permissive cell models, although SARS-CoV-2 infection induced the transcriptional upregulation of numerous chemokines, cytokines and interferon stimulated genes, many of these mRNAs were not translated efficiently. Impact of SARS-CoV-2 on host mRNA translation was more subtle in primary cells, with marked transcriptional and translational upregulation of inflammatory and innate immune responses and downregulation of processes involved in ciliated cell function. Together, these data reveal the key role of mRNA translation in SARS-CoV-2 replication and highlight unique mechanisms for therapeutic development.
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.biorxiv.org/content/10.1101/2020.11.03.367516v3" target="_blank">The translational landscape of SARS-CoV-2 and infected cells</a>
</div></li>
<li><strong>Comparison of MIS-C Related Myocarditis, Classic Viral Myocarditis, and COVID-19 Vaccine related Myocarditis in Children</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Background: Although rare, myocarditis in the pediatric population is a disease process that carries significant morbidity and mortality. Prior to the SARS-CoV-2 related (COVID-19) pandemic, enteroviruses were the most common cause of classic myocarditis. However, since 2020, myocarditis linked to multisystem inflammatory syndrome in children (MIS-C) is now common. In recent months, myocarditis related to COVID-19 vaccines has also been described. This study aims to compare these three different types of myocarditis with regards to clinical presentation, course, and outcomes. Methods: In this retrospective cohort study, we included all patients &lt;21 years of age hospitalized at our institution with classic viral myocarditis from 2015-2019, MIS-C myocarditis from 3/2020-2/2021 and COVID-19 vaccine-related myocarditis from 5/2021-6/2021. We compared demographics, initial symptomatology, treatment, laboratory data, and echocardiogram findings. Results: Of 201 total participants, 43 patients had classic myocarditis, 149 had MIS-C myocarditis, and 9 had COVID-19 vaccine-related myocarditis. Peak troponin was highest in the classic myocarditis group, whereas the MIS-C myocarditis group had the highest recorded brain natriuretic peptide (BNP). There were significant differences in time to recovery of normal left ventricular ejection fraction (LVEF) for the three groups: nearly all patients with MIS-C myocarditis (n=139, 93%) and all patients with COVID-19 vaccine-related myocarditis (n=9, 100%) had normal LVEF at the time of discharge, but a lower proportion of the classic myocarditis group (n=30, 70%) had a normal LVEF at discharge (p&lt;0.001). Three months post-discharge, 18 of 40 children (45%) in the classic myocarditis group still required heart failure treatment, whereas only one of the MIS-C myocarditis patients and none of the COVID-19 vaccine- associated myocarditis patients did. Conclusions: Compared to those with classic myocarditis, those with MIS-C myocarditis had more significant hematologic derangements and worse inflammation at presentation, but had better clinical outcomes, including rapid recovery of cardiac function. Patients with COVID-19 vaccine-related myocarditis had similar clinical presentation to patients with classic myocarditis, but their pattern of recovery was similar to those with MIS-C, with prompt resolution of symptoms and improvement of cardiac function. Long-term follow-up should focus on cardiac and non-cardiac consequences of myocarditis associated with COVID-19 illness and vaccination. Key Words: MIS-C, myocarditis, COVID-19, mRNA vaccine
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.10.05.21264581v1" target="_blank">Comparison of MIS-C Related Myocarditis, Classic Viral Myocarditis, and COVID-19 Vaccine related Myocarditis in Children</a>
</div></li>
</ul>
<h1 data-aos="fade-right" id="from-clinical-trials">From Clinical Trials</h1>
<ul>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Prophylaxis of COVID-19 Disease With Ivermectin in COVID-19 Contact Persons [German: Prophylaxe Der COVID-19-Erkrankung Mit Ivermectin Bei COVID-19 Kontaktpersonen]</strong> - <b>Condition</b>:   Covid19<br/><b>Interventions</b>:   Drug: Ivermectin;   Drug: Placebo<br/><b>Sponsors</b>:  <br/>
Infectopharm Arzneimittel GmbH;   GKM Gesellschaft für Therapieforschung mbH<br/><b>Not yet recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Evaluating Safety, Tolerability, and Potential Efficacy of Intranasal AD17002 in Adults With Mild COVID-19</strong> - <b>Condition</b>:   Covid19<br/><b>Interventions</b>:   Biological: AD17002;   Biological: Placebo (Formulation buffer)<br/><b>Sponsor</b>:   Advagene Biopharma Co. Ltd.<br/><b>Not yet recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Lymphatic Osteopathic Manipulative Medicine to Enhance Coronavirus (COVID-19) Vaccination Efficacy</strong> - <b>Condition</b>:   COVID-19<br/><b>Interventions</b>:   Other: Lymphatic OMM;   Other: Light Touch<br/><b>Sponsor</b>:   Rowan University<br/><b>Not yet recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A Study of AZD1222, a Vaccine for the Prevention of COVID-19 in Immunocompromised Adults</strong> - <b>Condition</b>:   COVID-19, SARS-CoV-2<br/><b>Intervention</b>:   Biological: AZD1222<br/><b>Sponsor</b>:  <br/>
AstraZeneca<br/><b>Not yet recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>“Efesovir” (FS-1) for COVID-19, Phase 2</strong> - <b>Condition</b>:   Covid19<br/><b>Intervention</b>:   Drug: Efesovir<br/><b>Sponsor</b>:   Scientific Center for Anti-infectious Drugs, Kazakhstan<br/><b>Not yet recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>SARS-CoV-2 Infection in COVID-19 Vaccinated Patients</strong> - <b>Condition</b>:   COVID-19<br/><b>Intervention</b>:   Diagnostic Test: COVID-19 vaccinated people<br/><b>Sponsor</b>:   Hospices Civils de Lyon<br/><b>Recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>The Development of a COVID19 Oral Vaccine Consisting of Bacillus Subtilis Spores</strong> - <b>Condition</b>:   COVID-19 Pneumonia<br/><b>Intervention</b>:   Biological: Bacillus subtilis<br/><b>Sponsor</b>:   DreamTec Research Limited<br/><b>Recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Phase I/II of the Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine in Healthy Populations</strong> - <b>Condition</b>:   Covid19<br/><b>Interventions</b>:   Biological: SARS-CoV-2 Protein Subunit Recombinant Vaccine;   Biological: SARS-CoV-2 Inactivated Vaccine<br/><b>Sponsors</b>:   PT Bio Farma;   Fakultas Kedokteran Universitas Indonesia;   National Institute of Health Research and Development, Ministry of Health Republic of Indonesia<br/><b>Not yet recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A Ph 2 Trial With an Oral Tableted COVID-19 Vaccine</strong> - <b>Condition</b>:   COVID-19<br/><b>Interventions</b>:   Drug: VXA-CoV2-1.1-S;   Other: Placebo Tablets<br/><b>Sponsor</b>:   Vaxart<br/><b>Recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Efficacy and Safety of Baricitinib in Patients With Moderate and Severe COVID-19</strong> - <b>Condition</b>:   Covid19<br/><b>Interventions</b>:   Drug: Baricitinib;   Drug: Placebo<br/><b>Sponsor</b>:  <br/>
Incepta Pharmaceuticals Ltd<br/><b>Not yet recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Randomized Trial of COVID-19 Booster Vaccinations (Cobovax Study)</strong> - <b>Condition</b>:   COVID-19 Vaccination<br/><b>Interventions</b>:   Biological: BNT162b2;   Biological: CoronaVac<br/><b>Sponsor</b>:   The University of Hong Kong<br/><b>Not yet recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>RCT on the Efficacy of Dexamethasone Versus Methyl Prednisolone in Covid-19 Infected Patients With High Oxygen Flow</strong> - <b>Condition</b>:   COVID-19 Pandemic<br/><b>Interventions</b>:   Drug: Dexamethasone;   Drug: Methylprednisolone<br/><b>Sponsor</b>:   Cairo University<br/><b>Recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Third Dose of mRNA Vaccination to Boost COVID-19 Immunity</strong> - <b>Condition</b>:   COVID 19 Vaccine<br/><b>Intervention</b>:   Biological: BNT162b2<br/><b>Sponsor</b>:  <br/>
The University of Hong Kong<br/><b>Recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells,NVSI-06-08) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above</strong> - <b>Conditions</b>:   COVID-19 Pneumonia;   Coronavirus Infections<br/><b>Interventions</b>:   Biological: Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-08);   Biological: COVID-19 vaccine (Vero cells);   Biological: 3 doses Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-08)<br/><b>Sponsors</b>:   National Vaccine and Serum Institute, China;   China National Biotec Group Company Limited;   Lanzhou Institute of Biological Products Co., Ltd<br/><b>Not yet recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Safety, Tolerability and Efficacy of Uproleselan (GMI-1271) in Patients With COVID-19 Pneumonia</strong> - <b>Condition</b>:   COVID-19 Pneumonia<br/><b>Intervention</b>:   Drug: Uproleselan<br/><b>Sponsors</b>:  <br/>
Lena Napolitano, MD;   GlycoMimetics Incorporated<br/><b>Not yet recruiting</b></p></li>
</ul>
<h1 data-aos="fade-right" id="from-pubmed">From PubMed</h1>
<ul>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Viral polymerase binding and broad-spectrum antiviral activity of molnupiravir against human seasonal coronaviruses</strong> - Endemic seasonal coronaviruses cause morbidity and mortality in a subset of patients, but no specific treatment is available. Molnupiravir is a promising pipeline antiviral drug for treating SARS-CoV-2 infection potentially by targeting RNA-dependent RNA polymerase (RdRp). This study aims to evaluate the potential of repurposing molnupiravir for treating seasonal human coronavirus (HCoV) infections. Molecular docking revealed that the active form of molnupiravir, β-D-N⁴-hydroxycytidine (NHC),…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Dissolving microneedle patches loaded with amphotericin B microparticles for localised and sustained intradermal delivery: Potential for enhanced treatment of cutaneous fungal infections</strong> - Fungal infections affect millions of people globally and are often unreceptive to conventional topical or oral preparations because of low drug bioavailability at the infection site, lack of sustained therapeutic effect, and the development of drug resistance. Amphotericin B (AmB) is one of the most potent antifungal agents. It is increasingly important since fungal co-infections associated with COVID-19 are frequently reported. AmB is only administered via injections (IV) and restricted to…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Inhibition of SARS-CoV-2 polymerase by nucleotide analogs from a single-molecule perspective</strong> - The absence of ‘shovel-ready’ anti-coronavirus drugs during vaccine development has exceedingly worsened the SARS-CoV-2 pandemic. Furthermore, new vaccine-resistant variants and coronavirus outbreaks may occur in the near future, and we must be ready to face this possibility. However, efficient antiviral drugs are still lacking to this day, due to our poor understanding of the mode of incorporation and mechanism of action of nucleotides analogs that target the coronavirus polymerase to impair…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Inhaled [D-Ala(2)]-Dynorphin 1-6 Prevents Hyperacetylation and Release of High Mobility Group Box 1 in a Mouse Model of Acute Lung Injury</strong> - COVID-19 is a respiratory infection caused by the SARS-CoV-2 virus that can rapidly escalate to life-threatening pneumonia and acute respiratory distress syndrome (ARDS). Recently, extracellular high mobility group box 1 (HMGB1) has been identified as an essential component of cytokine storms that occur with COVID-19; HMGB1 levels correlate significantly with disease severity. Thus, the modulation of HMGB1 release may be vital for treating COVID-19. HMGB1 is a ubiquitous nuclear DNA-binding…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>COVID-19 and the global need for knowledge on nurses’ health</strong> - CONCLUSIONS: These issues are reflected in the limited capacity of many national public health information systems to collect, monitor and report on the health of the largest group of health workers. Political will, accountability and public data transparency at different levels are essential to adequately protect nurses at work.</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Highly efficient SARS-CoV-2 infection of human cardiomyocytes: spike protein-mediated cell fusion and its inhibition</strong> - Severe cardiovascular complications can occur in coronavirus disease of 2019 (COVID-19) patients. Cardiac damage is attributed mostly to the aberrant host response to acute respiratory infection. However, direct infection of cardiac tissue by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) also occurs. We examined here the cardiac tropism of SARS-CoV-2 in spontaneously beating human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs). These cardiomyocytes express the…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Reductionism Ad Absurdum: The Misadventures of Structural Biology in the Time of Coronavirus</strong> - The tragic consequences of the COVID-19 pandemic have led to admirable responses by the global scientific community, including a profound acceleration in the pace of research and exchange of findings. However, this has had considerable costs of its own, as erroneous conclusions have propagated faster than researchers have been able to detect and correct them. We illustrate the specific misunderstandings that have resulted from reductionist approaches to the study of SARS- CoV-2 RNA-dependent RNA…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Antiviral effects of human placenta hydrolysate (Laennec()) against SARS-CoV-2 in vitro and in the ferret model</strong> - The COVID-19 pandemic has caused unprecedented health, social, and economic crises worldwide. However, to date, there is an only a limited effective treatment for this disease. Human placenta hydrolysate (hPH) has previously been shown to be safe and to improve the health condition in patients with hyperferritinemia and COVID-19. In this study, we aimed to determine the antiviral effects of hPH against SARS-CoV-2 in vitro and in vivo models and compared with Remdesivir, an FDA-approved drug for…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>PABPC4 Broadly Inhibits Coronavirus Replication by Degrading Nucleocapsid Protein through Selective Autophagy</strong> - Emerging coronaviruses (CoVs) can cause severe diseases in humans and animals, and, as of yet, none of the currently available broad-spectrum drugs or vaccines can effectively control these diseases. Host antiviral proteins play an important role in inhibiting viral proliferation. One of the isoforms of cytoplasmic poly(A)-binding protein (PABP), PABPC4, is an RNA-processing protein, which plays an important role in promoting gene expression by enhancing translation and mRNA stability. However,…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>The key role of the central cavity in sodium transport through ligand-gated two-pore channels</strong> - Subcellular and organellar mechanisms have manifested a prominent importance for a broad variety of processes that maintain cellular life at its most basic level. Mammalian two-pore channels (TPCs) appear to be cornerstones of these processes in endo-lysosomes by controlling delicate ion-concentrations in their interiors. With evolutionary remarkable architecture and one-of-a-kind selectivity filter, TPCs are an extremely attractive topic per se. In the light of the current COVID-19 pandemic,…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Anti-PF4 VITT antibodies are oligoclonal and variably inhibited by heparin</strong> - CONCLUSION: Oligoclonal anti-PF4 antibodies mediate VITT. Heparin use in VITT needs to be further studied.</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Viral replication in human macrophages enhances an inflammatory cascade and interferon driven chronic COVID-19 in humanized mice</strong> - Chronic COVID-19 is characterized by persistent viral RNA and sustained interferon (IFN) response which is recapitulated and required for pathology in SARS-CoV-2 infected MISTRG6-hACE2 humanized mice. As in the human disease, monocytes, and macrophages in SARS-CoV-2 infected MISTRG6-hACE2 are central to disease pathology. Here, we describe SARS-CoV-2 uptake in tissue resident human macrophages that is enhanced by virus specific antibodies. SARS-CoV-2 replicates in these human macrophages as…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Estrogen Hormone Is an Essential Sex Factor Inhibiting Inflammation and Immune Response in COVID-19</strong> - Although vaccines have been evaluated and approved for SARS-CoV-2 infection prevention, there remains a lack of effective treatments to reduce the mortality of COVID-19 patients already infected with SARS-CoV-2. The global data of COVID-19 showed that men have a higher mortality rate than women. We further observed that the proportion of mortality of female increases starting from around the age of 55 significantly. Thus, sex is an essential factor associated with COVID-19 mortality, and sex…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Tocilizumab reduces COVID-19 mortality and pathology in a dose and timing-dependent fashion: a multi-centric study</strong> - Life-threatening COVID-19 is associated with strong inflammation, where an IL-6-driven cytokine storm appears to be a cornerstone for enhanced pathology. Nonetheless, the specific inhibition of such pathway has shown mixed outcomes. This could be due to variations in the dose of tocilizumab used, the stage in which the drug is administered or the severity of disease presentation. Thus, we performed a retrospective multicentric study in 140 patients with moderate to critical COVID-19, 79 of which…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>The Importance of the Timing of Tocilizumab Administration in Moderate to Severely Ill COVID-19: Single Centered Experience Case series</strong> - One of the main causes of death in COVID-19 is the dysregulation of the host’s immune system which leads to cytokine storm, a potentially fatal systemic inflammatory syndrome. Interleukin 6 (IL-6) is a pro-inflammatory cytokine that is produced in response to infections and tissue injuries and is believed to play a pivotal role in the event of a cytokine storm, as signified by its increase in the process. Considering the role of IL-6 as a pro-inflammatory cytokine in the process of cytokine…</p></li>
</ul>
<h1 data-aos="fade-right" id="from-patent-search">From Patent Search</h1>
<ul>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>스몰 RNA 검출 방법</strong> - 본 발명은 스몰(small) RNA의 분석 및 검출 방법에 관한 것이다. 특히, 본 발명은 짧은 염기서열의 RNA까지 분석이 가능하면서도 높은 민감도 및 정확도로 정량적 검출까지 가능하여 감염증, 암 등 여러 질환의 진단 용도로도 널리 활용될 수 있다. - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=KR336674313">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>健康智能检测方法、装置、电子设备及可读存储介质</strong> - 本申请公开了一种健康智能检测方法、装置、电子设备及可读存储介质，其方法包括获取音频信号，并对所述音频信号进行预处理，得到检测信号；将所述检测信号转化为矩阵数字矩阵；将得到的矩阵数字矩阵作为检测样本，输入健康智能检测模型中，以获取检测结果；其中，所述健康智能检测模型是采用迁移学习和卷积神经网络对训练样本进行训练得到的。本申请由于卷积神经网络各组件或部分组件基于迁移学习进行了重新训练，显著提升了对人们健康检测的准确度；且本申请中的健康智能检测模型为分类模型，计算量小，可将其部署于人们的移动终端中，使用方便，极大程度上提升了用户的使用感受。 - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=CN337672106">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>MACHINE LEARNING TECHNIQUE TO ANALYSE THE CONDITION OF COVID-19 PATIENTS BASED ON THEIR SATURATION LEVELS</strong> - - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=AU335054861">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>单克隆抗体32C7及其制备方法和用途</strong> - 本发明公开了单克隆抗体32C7及其制备方法和用途。本发明通过制备针对于新冠病毒RBD结构域的中和抗体32C7，在体外通过表面等离子共振检测抗体32C7可以有效地与新冠病毒的S蛋白的RBD结构域结合，通过转基因小鼠感染模型验证了抗体32C7的中和能力，测定了中和抗体32C7对于新冠感染后的肺部病毒滴度和相关炎症因子的抑制效果，结果显示该中和抗体能够明显的抑制病毒在体内的复制并降低炎症因子的产生和肺部炎症浸润。单克隆中和抗体32C7抑制新冠病毒的进入宿主细胞，达到新冠病毒中和抗体的治疗作用，可有效用于治疗或者预防新冠病毒感染引起的呼吸系统损伤。 - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=CN336730149">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>单克隆抗体35B5及其制备方法和用途</strong> - 本发明公开了单克隆抗体35B5及其制备方法和用途。本发明通过制备针对于新冠病毒RBD结构域的中和抗体35B5，在体外通过表面等离子共振检测抗体35B5可以有效地与新冠病毒的S蛋白的RBD结构域结合，通过转基因小鼠感染模型验证了抗体35B5的中和能力，测定了中和抗体35B5对于新冠感染后的肺部病毒滴度和相关炎症因子的抑制效果，结果显示该中和抗体能够明显的抑制病毒在体内的复制并降低炎症因子的产生和肺部炎症浸润。单克隆中和抗体35B5抑制新冠病毒的进入宿主细胞，达到新冠病毒中和抗体的治疗作用，可有效用于治疗或者预防新冠病毒感染引起的呼吸系统损伤。 - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=CN336730150">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A HERB BASED COMPOSITION ANTI VIRAL MEDICINE FOR TREATMENT OF SARS COV 2 AND A METHOD FOR TREATING A PERSON INFECTED BY THE SARS COV 2 VIRUS</strong> - A Herbal composition, viz., PONNU MARUNTHU essentially comprising of ALLUIUM CEPA extract. [concentrated to 30%] 75%, SAPINDUS MUKOROSSI - extract [Optimised] 10%, CITRUS X LIMON - extract in its natural form 05 TRACYSPERMUM AMMI (L) – extract 07%,ROSA HYBRIDA - extract 03%, PONNU MARUNTHU solution 50 ml, or as a capsulated PONNU MARUNTHU can be given to SARS cov2 positive Patients, three times a day that is ½ an hour before food; continued for 3 days to 5 days and further taking it for 2 days if need be there; It will completely cure a person. When the SARS cov2 test shows negative this medicine can be discontinued. This indigenous medicine and method for treating a person inflicted with SARS COV 2 viral infection is quite effective in achieving of much needed remedy for the patients and saving precious lives from the pangs of death and ensuring better health of people. - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=IN334865051">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>治疗或预防新冠病毒的靶点</strong> - 本发明提供一种蛋白片段，是如下至少一种：A1)氨基酸酸序列如SEQ ID NO.1所示；A2）氨基酸序列如SEQ ID NO.1第12位‑34位所示；A3）将A1)的蛋白片段的第18、19、28和29位中的任意一个或几个氨基酸残基经过一个或几个氨基酸残基的取代、缺失、添加得到的与A1)所示的蛋白片段具有90％以上的同一性的蛋白片段；A4）氨基酸酸序列如SEQ ID NO.2所示；A5）氨基酸序列如SEQ ID NO.2第32‑41位所示；A6）将A4)的蛋白片段的第35和36位中的任意1个或2个氨基酸残基经过一个或几个氨基酸残基的取代、缺失、添加得到的与A4)所示的蛋白片段具有90％以上的同一性的蛋白片段。 - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=CN336197499">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>以痘苗病毒为载体的新冠疫苗</strong> - 本申请涉及一种基于经过基因工程改造的痘苗病毒为载体的新型冠状病毒南非突变株疫苗。所述疫苗以A46R缺陷的痘苗病毒为载体携带新冠病毒南非突变株S基因核酸序列，所述痘苗病毒载体还可以携带IL‑21，该疫苗在免疫小鼠后可以产生针对新冠病毒南非突变株的抗体。 - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=CN337671415">link</a></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>氧化钛负载银单原子的材料在病毒消杀中的应用</strong> - 本发明属于生物医药领域，尤其涉及一种负载银单原子的材料在病毒消杀中的应用，所述氧化钛负载银单原子材料具有以下的结构：银单原子以单分散的形式，稳定地锚定于氧化钛的表面和/或骨架中，键合方式为Ti‑O‑Ag；银单原子的嵌合使Ag单原子和氧化钛的电子结构带隙范围为2.9‑3.2</p></li>
</ul>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">eV；氧化钛负载银单原子材料具有较银纳米颗粒更加优异的催化活性，具有过氧化物酶活性，利用羟基自由基可高效破坏核酸和蛋白质的原理来实现广谱消杀病毒，银单原子的嵌合使Ag单原子和氧化钛的电子结构带隙变小，对可见光的敏感性更强，可将光照射下的光催化诱导光动力杀伤病毒。 - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=CN337671299">link</a></p>
<ul>
<li><strong>Anti-Sars-Cov-2 Neutralizing Antibodies</strong> - - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=AU333857732">link</a></li>
</ul>
<script>AOS.init();</script></body></html>

508
archive-daily-dose/08 October, 2021.html Normal file
View File

@ -0,0 +1,508 @@
<!DOCTYPE html>
<html lang="" xml:lang="" xmlns="http://www.w3.org/1999/xhtml"><head>
<meta charset="utf-8"/>
<meta content="pandoc" name="generator"/>
<meta content="width=device-width, initial-scale=1.0, user-scalable=yes" name="viewport"/>
<title>08 October, 2021</title>
<style type="text/css">
code{white-space: pre-wrap;}
span.smallcaps{font-variant: small-caps;}
span.underline{text-decoration: underline;}
div.column{display: inline-block; vertical-align: top; width: 50%;}
</style>
<title>Daily-Dose</title><meta content="width=device-width, initial-scale=1.0" name="viewport"/><link href="styles/simple.css" rel="stylesheet"/><link href="../styles/simple.css" rel="stylesheet"/><style>*{overflow-x:hidden;}</style><link href="https://unpkg.com/aos@2.3.1/dist/aos.css" rel="stylesheet"/><script src="https://unpkg.com/aos@2.3.1/dist/aos.js"></script></head>
<body>
<h1 data-aos="fade-down" id="daily-dose">Daily-Dose</h1>
<h1 data-aos="fade-right" data-aos-anchor-placement="top-bottom" id="contents">Contents</h1>
<ul>
<li><a href="#from-new-yorker">From New Yorker</a></li>
<li><a href="#from-vox">From Vox</a></li>
<li><a href="#from-the-hindu-sports">From The Hindu: Sports</a></li>
<li><a href="#from-the-hindu-national-news">From The Hindu: National News</a></li>
<li><a href="#from-bbc-europe">From BBC: Europe</a></li>
<li><a href="#from-ars-technica">From Ars Technica</a></li>
<li><a href="#from-jokes-subreddit">From Jokes Subreddit</a></li>
</ul>
<h1 data-aos="fade-right" id="from-new-yorker">From New Yorker</h1>
<ul>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>How Biden Came to Own Trump’s Policy at the Border</strong> - Haitian asylum seekers were deported under Title 42, a despised Trump-era practice that the current Administration can’t seem to let go of. - <a href="https://www.newyorker.com/news/daily-comment/how-biden-came-to-own-trumps-policy-at-the-border">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>The Challenges of Regulating Cryptocurrency</strong> - The S.E.C. has yet to set clear rules on cryptocurrencies, leaving the industry guessing. Maybe that’s just how the agency wants it. - <a href="https://www.newyorker.com/business/currency/the-challenges-of-regulating-cryptocurrency">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>How Texas Abortion Volunteers Are Adapting After S.B. 8</strong> - In addition to helping people get to abortion appointments out of state, volunteer groups have been inundated with requests to deliver Plan B pills and pregnancy tests. - <a href="https://www.newyorker.com/news/annals-of-activism/how-texas-abortion-volunteers-are-adapting-after-sb-8">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>The Battle of January 6th Has Just Begun</strong> - Nine months after the storming of the Capitol, Trump is more popular with the G.O.P. and his Big Lie is more widely believed. - <a href="https://www.newyorker.com/news/letter-from-bidens-washington/the-battle-of-january-6th-has-just-begun">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>The Moral Bankruptcy of Facebook</strong> - The whistle-blower Frances Haugen hoped that her revelations would prompt a reckoning. Instead, the company has doubled down. - <a href="https://www.newyorker.com/news/daily-comment/the-moral-bankruptcy-of-facebook">link</a></p></li>
</ul>
<h1 data-aos="fade-right" id="from-vox">From Vox</h1>
<ul>
<li><strong>Is Biden’s legislative agenda popular? Yes, but …</strong> -
<figure>
<img alt="President Joe Biden sitting at a conference table with a window behind him." src="https://cdn.vox-cdn.com/thumbor/5zqy7LVDfGqABsaXhdD8N_osS64=/592x0:5331x3554/1310x983/cdn.vox-
cdn.com/uploads/chorus_image/image/69968531/GettyImages_1345175573__1_.0.jpg"/>
<figcaption>
President Joe Biden meeting with corporate executives and members of his Cabinet to discuss the federal debt limit on October 6, 2021, in Washington, DC. | Chip Somodevilla/Getty Images
</figcaption>
</figure>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
The complicated politics of Democrats’ reconciliation bill.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="U9ZCn8">
On the surface, this week’s <a href="https://poll.qu.edu/poll-
release?releaseid=3823">new poll from Quinnipiac University</a> had good news for Democrats about <a href="https://www.vox.com/22577374/reconciliation-bill-biden-medicare-climate">the big spending bill</a> the party is trying to pass through Congress. Presented with a description of the bill’s $3.5 trillion price tag and some of its priorities, 57 percent of adults polled said they supported it, and only 40 percent were opposed — good numbers for this polarized country.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="9gFFOF">
But that same poll had a more ominous finding for Democrats: A plurality of voters said they wanted Republicans to regain control of the House of Representatives. Just 43 percent of adults surveyed wanted to keep Democrats in charge of the chamber, compared to 46 percent who wanted the GOP to take over.
</p></li>
</ul>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="dsrUyA">
These are the unusual political dynamics around President Joe Biden’s top legislative priority, known as the Build Back Better Act. People think it sounds good. There’s not much of a <a href="https://www.vox.com/22245242/democratic-agenda-backlash-biden-midterms">backlash</a>. But it doesn’t seem to be the key to Democrats’ future electoral success, either, if many swing voters vote for the party that opposes it in the next election.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="BC2On5">
This may be because many Americans simply don’t yet know what’s in the bill, so the stakes aren’t yet concrete for them. The bill has only recently started to dominate headlines, and the emphasis has often been on Democratic disarray and legislative drama rather than on <a href="https://thecolumn.substack.com/p/the-
actual-human-stakes-of-the-reconciliation?justPublished=true">what the bill proposes to do for people</a>. I’ve written an <a href="https://www.vox.com/22577374/reconciliation-bill-biden-medicare-climate">extensive rundown</a> of what may be included in the bill, and the information is out there for those who seek it out, but these details have often been absent from media coverage.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="2HdJZF">
Another possibility is that there’s a disconnect between the forward- looking ambitions of the Build Back Better Act and the current situation in the country. As <a href="https://www.bloomberg.com/opinion/articles/2021-10-03/biden-and-democrats-need-more-short-term-thinking-about-
economy">Matt Yglesias writes</a>, this bill was largely crafted in a pre-delta-variant world. The administration expected it would be debated when the Covid-19 pandemic was all but defeated domestically and the economy was roaring back. The bill was meant to be a pivot from a successful crisis response to the Democratic coalition’s long-held priorities. But the <a href="https://www.vox.com/e/22476778">crisis is largely still here</a>, and voters know it.
</p>
<h3 id="Al4kQ3">
How to think about the Build Back Better Act
</h3>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="4zIBKX">
It’s difficult to place the Build Back Better Act on the ideological spectrum. On the one hand, it spends trillions on progressive priorities, and Sen. Bernie Sanders is a big fan. On the other hand, it’s been carefully designed so it avoids hot-button social issues and doesn’t take anything away from anyone except rich people and corporations. The major beneficiaries include the poor and clean energy industries but also many seniors and parents. It’s a big and significant bill, but not really a radical one.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="FUndON">
The bill is essentially a grab bag, combining the top priorities that President Biden campaigned on with those of congressional Democrats — at least, all the priorities that qualify for the Senate’s special filibuster-proof budget reconciliation process. Everything in the bill has to clearly affect the federal budget, so there’s nothing about <a href="https://www.vox.com/22346812/voting-rights-bill-hr1-for-the-people-act">voting rights</a>, immigration provisions <a href="https://www.cnn.com/2021/09/29/politics/senate-parliamentarian-immigration-budget-
economy/index.html">may be dropped</a>, and its provisions are generally about spending money rather than changing regulations.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="ND7ZmT">
Still, the current version of the bill tries to tackle <a href="https://www.vox.com/22577374/reconciliation-bill-biden-medicare-climate">a great many things</a> — fighting poverty, combating climate change, expanding health care benefits, helping with child-raising expenses, offering universal pre-K and free community college, housing policy, tax policy, and more. (Moderate Democrats like Sen. <a href="https://www.vox.com/22339531/manchin-filibuster-bipartisanship-senate-west-virginia">Joe Manchin</a> of West Virginia may force some of these policies to be cut back or dropped in the final version.)
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="szc1fm">
The pandemic crisis doesn’t necessarily make these issues less important. Indeed, some of them, like burdensome child care expenses and gaps in the safety net, are arguably more urgent. Other problems, like the climate, <a href="https://www.vox.com/22685920/democrats-infrastructure-build-back-better-climate-change">certainly aren’t just going away</a>. And the bill extends some important measures first passed in the pandemic relief bill, like the expanded child tax credit.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="8uFjlI">
But overall, this is a bill crafted to advance long-held priorities of the Democratic coalition — not, necessarily, one aimed at addressing issues that are top of mind for swing voters, or that will help the party most electorally. A bill like that might be more laser-focused on the pandemic or the economy.
</p>
<h3 id="YHL5Va">
The politics of Obamacare compared to those of Build Back Better
</h3>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="Fgoz6w">
In that, there’s one major similarity to the first-year legislative agenda of President Barack Obama.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="x9TZpe">
Elected in the midst of the Great Recession, Obama spent his first few months dealing with the economic crisis before pivoting to trying to pass his major health reform bill — a longtime Democratic priority.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="Fv7WsV">
The problem was that the economic crisis was not yet fixed — the unemployment rate remained stubbornly high. And though he passed the Affordable Care Act, his approval rating dropped, and Democrats were shellacked in the ensuing 2010 midterms.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="sUjKBl">
History could be repeating itself. Currently, the pandemic, the economy, and “poor leadership” are the top problems American adults think are facing the country, <a href="https://news.gallup.com/poll/355511/gop-viewed-better-
party-security-prosperity.aspx">according to a recent Gallup poll</a>. Relatively few respondents named climate change, health care, or poverty as their top priority, but those are the top issues tackled in Biden’s bill.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="zIkYuj">
Still, there are major differences with how the debate over the Build Back Better Act has played out so far.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="1BguJg">
Obamacare <a href="https://www.pewresearch.org/politics/2009/10/08/mixed-views-of-economic-
policies-and-health-care-reform-persist/">polled poorly</a> by this point in 2009; Biden’s bill doesn’t. The intense backlash on the right that ensued over Obamacare has not materialized this time around — Republican politicians are opposing it, but the GOP base seems more energized by culture war issues and the pandemic.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="UGKARD">
Biden’s bill also hasn’t dominated public and media attention like the many-months-long Obamacare debate. This may be a consequence of crafting a bill that does so many things, but that is also designed to be unobjectionable: It lacks the central story and conflict that media outlets search for when they make programming choices. Often, more dramatic issues like the pandemic and the pullout of troops from Afghanistan have dominated headlines instead. And when the bill does come to the fore, the frame is usually about how Democrats are fighting over it and struggling to reach agreement, not about what the bill would do.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="EsfaA6">
Perhaps, as Speaker Nancy Pelosi <a href="https://www.vox.com/policy-
and-politics/2017/3/18/14957708/pelosi-pass-the-bill">once famously said</a> about Obamacare, Democrats have to pass the Build Back Better Act so the public can find what’s in it. That is, once members of the public start getting the benefits from this bill, it will become popular — as happened with Obamacare. That does not mean that this bill will become a vote-winner for Democrats, but it could ensure achievements stand the test of time or make it more likely that Republicans shy away from repealing it once they retake power.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="TBjMP6">
Moderate Democrats, though, might point to the lack of evidence that the Build Back Better Act is helping the party electorally and suggest cutting it back or dropping it. That perhaps the party should just pass <a href="https://www.vox.com/22598883/infrastructure-deal-
bipartisan-bill-biden-manchin">the infrastructure bill</a> that has already won bipartisan Senate support through the House instead.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="cxXIcm">
But that doesn’t necessarily follow. The <a href="https://projects.fivethirtyeight.com/trump-approval-ratings/">lowest President Trump’s approval ever dropped</a> was in December 2017, when it looked like congressional Republicans were about to botch tax reform and make his presidency a total failure. Even hardcore Republicans started to get fed up at that point. But the GOP soon got it together and passed its tax bill. Trump’s popularity rebounded a bit and never returned to that previous low point, even after his attempt to overturn the election result. Looking like a loser can be a political problem of its own.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="OM0mIU">
The reality for Democrats is that the 2022 elections will be tremendously difficult regardless of whether this bill passes or fails. A new president’s party <a href="https://www.vox.com/2014/8/4/5960095/what-would-it-take-for-
democrats-to-win-the-house">very often loses House seats</a> in the midterms, and Democratic majorities in both chambers are very narrow. The reconciliation bill may not save them, but losing it could well sink them.
</p>
<ul>
<li><strong>The best- and worst-case scenarios for Covid-19 this winter</strong> -
<figure>
<img alt="An illustration of a woman wearing a face mask" src="https://cdn.vox-
cdn.com/thumbor/B9QBagmjGTEeIjOg35ooql-Ahf8=/51x0:2718x2000/1310x983/cdn.vox-
cdn.com/uploads/chorus_image/image/69968398/GettyImages_1209437279_copy.0.jpg"/>
<figcaption>
Experts say Covid-19 cases and deaths should not be as bad in the US this winter as they were last winter. But there is a lot of uncertainty. | Getty Images
</figcaption>
</figure>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Why this winter should be better than the last one.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="PTb51o">
The <a href="https://www.vox.com/coronavirus-covid19/22576904/us-new-covid-cases-rising-again-delta-
variant">summer wave of Covid-19 cases and deaths</a> is finally starting to fade, but already, winter is within sight.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="GHBArQ">
Last December and January, the United States and much of the world experienced the deadliest surges of the pandemic. At one point, more than 3,000 Americans <a href="https://www.nytimes.com/interactive/2021/us/covid-cases.html">were dying every day of Covid-19</a>. Nearly 250,000 people <a href="https://ourworldindata.org/explorers/coronavirus-data-
explorer?zoomToSelection=true&amp;time=2020-12-01..2021-02-28&amp;facet=none&amp;pickerSort=desc&amp;pickerMetric=new_deaths_per_million&amp;Metric=Confirmed+deaths&amp;Interval=Cumulative&amp;Relative+to+Population=false&amp;Align+outbreaks=false&amp;country=~USA">died in the United States</a> over December, January, and February.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="EnkZBL">
But this winter may be different, at least in America. Last year, almost nobody was vaccinated against Covid-19. As of October 7, 56 percent of the US population is fully vaccinated, according to <a href="https://www.nytimes.com/interactive/2020/us/covid-19-vaccine-
doses.html">the New York Times’s tracker</a>. That includes 84 percent of people over 65, who are generally the most vulnerable to dying from the virus. The Food and Drug Administration <a href="https://www.nytimes.com/2021/10/07/us/politics/pfizer-fda-authorization-children-5-11.html">will soon consider</a> whether to authorize a vaccine for children as young as 5, which would push vaccination rates higher.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="8ySihH">
More than half the population being vaccinated is the primary reason for optimism about the coming months. Some number of unvaccinated people have natural immunity as well; there have been 44 million recorded cases of Covid-19 in the US to date.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="qHUXHy">
At some point, the virus starts to run out of people with no protection to infect. While there will be <a href="https://www.vox.com/22602039/breakthrough-cases-covid-19-delta-variant-masks-
vaccines">breakthrough cases</a> within the vaccinated population, those people are significantly less likely to develop serious symptoms than if they were unvaccinated. At this stage, the major goals are maintaining hospital capacity to make sure health systems are not so inundated with patients that they must ration care and preventing deaths. The more people with immunity; the fewer deaths we will see. That’s the main reason this winter could be better than last.
</p></li>
</ul>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="mQVxZH">
The Covid Scenario Modeling Hub, which is a synthesis of several projections of future case and death numbers, <a href="https://covid19scenariomodelinghub.org/viz.html">shows</a> US Covid-19 deaths steadily falling, from an average of nearly 2,000 per day during the last week of September to a projected 90 deaths per day in the final week of February 2022.
</p>
<aside id="CFSiq3">
<div>
</div>
</aside>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="yR0wCl">
But that is assuming a lot of children get vaccinated and no new variant emerges that is more transmissible and/or deadly than the delta variant. Under different parameters, if few children get vaccinated and a new variant does become dominant, the coming winter could look a lot different. The <a href="https://covid19scenariomodelinghub.org/">Covid Scenario Modeling Hub</a> projects about 650 deaths every day by the end of February in that scenario — and trending upward. That’s not as bad as the last winter, but it is still much worse than other possible futures. (And to be clear: All the scenarios involve significant uncertainty in the specific numbers projected.)
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="3k1aAH">
Which situation we end up in will depend in part on luck (hopefully, the virus does not suddenly become more virulent) and in part on our own decisions (such as whether or not to get vaccinated — which can help stave off new variants).
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="ZO9HAc">
We likely will end up seeing both scenarios play out in different places. Areas with a lot of immunity, whether by vaccination or infection, may have an easier winter. But there are still pockets of people, in areas as small as a town or even a neighborhood, where there is not much immunity and a lot of people are still vulnerable to Covid-19. They are facing a much harder winter.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="ajYHjS">
Here’s what will determine how the United States fares during the cold-weather months.
</p>
<h3 id="3gqBPO">
The reasons for optimism about Covid-19 this winter
</h3>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="axiH8w">
More vaccinations should mean a better winter. Other factors — how much people travel, what precautions they take to social distance, etc. — will play a role, but nothing is as likely to influence how the winter unfolds as vaccination rates.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="axCAT3">
At this point, about 75 percent of Americans ages 12 and older <a href="https://www.nytimes.com/interactive/2020/us/covid-19-vaccine-doses.html">have received</a> at least one dose of a Covid-19 vaccine. Most importantly, 95 percent of people over 65 have gotten at least one dose, and the federal government has signed off on <a href="https://www.vox.com/coronavirus-covid19/2021/9/24/22691355/covid-booster-shot-cdc-
fda-pfizer-approval">booster shots</a> for that age group. And Pfizer has <a href="https://www.nytimes.com/2021/10/07/us/politics/pfizer-fda-authorization-children-5-11.html">asked the FDA</a> to approve its vaccine for children ages 5 to 11, which sets the stage for vaccinations to begin for the school-aged population in a matter of weeks.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="G0Hyj3">
President Joe Biden’s administration and many states, cities, and employers are doing whatever they can to encourage more vaccinations. The federal government is <a href="https://www.vox.com/22666625/biden-vaccine-mandate-covid-19-supreme-court-osha-constitution-legal">requiring</a> large employers to institute vaccine mandates; some local governments and businesses are <a href="https://www.vox.com/22599791/covid-vaccine-mandate-legal-joe-biden-supreme-court-jacobson-massachusetts-boss-
employer">doing the same</a>. Daily vaccination rates are still far below their peak of more than 3 million in April, but they have picked up over the past few months, from a low of about 500,000 per day on average in mid-July to about 950,000 daily in early October.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="5dKezi">
“Vaccination coverage is creeping up and that, combined with natural immunity, affords increasing protection,” Jennifer Kates, director of global health policy at the Kaiser Family Foundation, told me. “Kids should be eligible soon. Even with kids back in school, we are not seeing big outbreaks. These are all signs that we could be over the significant hump.”
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="hWkoPa">
The US is entering a new stage of its epidemic. Covid-19 is not going away, so we will have to decide, individually and collectively, <a href="https://www.vox.com/22621760/covid-19-risk-delta-vaccines-provincetown-study">how much risk</a> we are willing to tolerate. It isn’t possible to prevent all infections, but the goal should be to prevent as much serious disease as possible in order to avoid hospitals being too overwhelmed to care for all their patients, a worst-case scenario that was <a href="https://www.vox.com/coronavirus-covid19/2021/9/14/22650733/us-covid-19-hospitals-full-texas-alabama">seen in the hardest-hit parts of the country this summer</a>.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="J5N2eu">
The vaccines continue to provide strong protection against severe illness for most people, and many people for whom vaccine effectiveness is more likely to wane are now eligible for booster shots. The more people are vaccinated, the more likely we can allow life to return to normal (or normal-ish) without risking overrun hospitals.
</p>
<div class="c-float-right c-float-hang">
<aside id="bdVkaE">
<q>“Even in the most highly vaccinated US states, there will still be a reservoir of people susceptible to the virus” —Josh Michaud, Kaiser Family Foundation</q>
</aside>
</div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="E4SwO7">
About half of unvaccinated US adults are open to getting the vaccine, according to <a href="https://www.kff.org/coronavirus-covid-19/poll-finding/kff-
covid-19-vaccine-monitor-september-2021/">the Kaiser Family Foundation’s September survey</a>, saying they are either still taking a “wait and see” approach or they’ll get it if required. Most vaccinated people say that they would get a booster if and when they are eligible for one. And about one-third of parents with kids ages 5 to 11 <a href="https://www.kff.org/coronavirus-covid-19/poll-finding/kff-covid-19-vaccine-monitor-trends-among-children-
school/">now say</a> they will get their child vaccinated right away, up from 26 percent who were saying the same in July.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="P1KEpJ">
All of those trends suggest there is room for the overall US vaccination rate to grow before the cold weather really sets in. That would portend a better winter than last year, even if experts caution it is still possible to see a small bump in cases under a best-case scenario.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="Zhx4HS">
Their goal is to have as many of the cases as possible be vaccinated people with mild symptoms that don’t require a trip to the hospital. That way, life could go on in relative safety.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="Q40z0J">
“It’s no secret that Covid will likely remain endemic and still hurt people,” Kumi Smith, an epidemiologist at the University of Minnesota, told me. “But if we can reliably send kids to school and give our health care systems a fighting chance, I️ think that will be a huge step.”
</p>
<h3 id="MNqET5">
The reasons for pessimism about a coming winter wave
</h3>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="w1uBma">
But in the same data, there are trends that could result in a more difficult winter, one in which many Americans remain unprotected from Covid, fully vulnerable to the delta variant — or, in the worst-case scenario, a more virulent successor.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="RtCpET">
About 12 percent of Americans say they will “definitely not” get the vaccine, under any circumstances, according to the KFF’s September poll. They appear unlikely to be moved by any incentives or requirements; some of them have become <a href="https://www.vox.com/coronavirus-covid19/22686147/covid-19-vaccine-betadine-hydroxychloroquine-ivermectin-trump-
conspiracy">a part of the anti-vaccine, pro-miracle cure community</a> that has developed during the pandemic and is not persuaded by the mainstream consensus.
</p>
<div class="c-float-left c-float-hang">
<aside id="VYdN1K">
<q>Covid-19 is not going away. We will have to decide, individually and collectively, how much risk we are willing to tolerate.</q>
</aside>
</div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="qNnTOF">
A lot of parents also appear hesitant to get their young children vaccinated, even after the FDA’s expected approval: Per the Kaiser poll, 32 percent of parents said in September that they will “wait and see” about it; 7 percent say they will have their kid get vaccinated only if required, and 24 percent say they will “definitely not” allow their child to be vaccinated. Such a large share of parents being hesitant about a new vaccine is actually not unique to Covid-19. As Aaron Carroll <a href="https://www.theatlantic.com/ideas/archive/2021/09/how-many-vaccinated-parents-will-vaccinate-their-
kids/620191/?utm_source=twitter&amp;utm_medium=social&amp;utm_campaign=share">wrote for the Atlantic</a>, it took years for chickenpox vaccination rates to reach 90 percent in the US.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="3a41sT">
So there will be pockets of the population who remain fully vulnerable to Covid-19. It doesn’t appear likely that the United States can reach sufficient vaccination levels to stop the virus’s transmission entirely. And even <a href="https://twitter.com/EricTopol/status/1444899816299905024">vaccinating many more kids may not help as much</a> as vaccinating more older adults would in reducing severe cases overall.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="GQd52T">
“Even in the most highly vaccinated US states, there will still be a reservoir of people susceptible to the virus,” Josh Michaud, associate director of global health policy at the Kaiser Family Foundation, told me. “No state has reached a level of population immunity that could interrupt spread — and that may not even be possible, given the highly transmissible delta variant.”
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="ZbXWfh">
Different places will have different levels of vulnerability, though, depending how much immunity there is through vaccinations and prior infections. Some states have vaccinated more than 99 percent of their over-65 population; others, like West Virginia and Wyoming, are still hovering closer to 80 percent, meaning a lot of the people most at risk from Covid-19 lack any immunity to the virus.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="gDHqHV">
That variance goes all the way to the local level. Wayne County, Michigan, is considered highly vulnerable to Covid-19, according to <a href="https://www.nytimes.com/interactive/2020/us/covid-19-vaccine-doses.html">the CDC’s Social Vulnerability Index</a>, which uses various socioeconomic measures to assess a place’s risk. The county’s vaccination rate is stuck at 46 percent, well below the overall state rate, and one in four people over 65 aren’t vaccinated.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="mQTvBl">
Bill Hanage, a Harvard University epidemiologist, told me this kind of micro-trend is one reason that clusters of cases continue to appear even in highly vaccinated areas.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="Ijy6E6">
“One obvious and important reason is the clustered nature of susceptible individuals,” he said. “If you are 95 percent vaccinated in your town, but the 5 percent unvaccinated are all in the meatpacking plant, that’s not good.”
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="8atiQ4">
So the US may end up experiencing both the best-case and worst-case scenarios simultaneously this winter, depending on where you live and who you are. But experts are consistent in saying that more vaccinations should lead to less risk — and help avert what they consider the worst-case scenario for the winter if vaccinations lag.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="HUZepQ">
“Worst-case scenario is that another variant emerges,” Kates said. “Covid has fooled us before and can again. And if people let their guard down — masking stopping too early, for example — we could see another surge, especially since we are entering winter.”
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="Uj93J9">
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="hD45VH">
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="6Nf28q">
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="x92BJK">
</p>
<ul>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>The debt ceiling fight is far from over</strong> -
<figure>
<img alt="" src="https://cdn.vox-
cdn.com/thumbor/XhTI4bPkRDoGwUn60KruOB4zyjE=/167x0:2834x2000/1310x983/cdn.vox-
cdn.com/uploads/chorus_image/image/69967155/GettyImages_1235752282.0.jpg"/>
<figcaption>
Senate Minority Leader Mitch McConnell walks to Senate Republican policy luncheons at the Capitol on October 7, 2021. | Stefani Reynolds/Bloomberg via Getty Images
</figcaption>
</figure>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Get ready to do this all again in December.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="36GjAv">
Lawmakers have ended another standoff over the debt ceiling — at least temporarily.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="ulbALn">
On Thursday, the Senate voted 50-48 to increase the debt ceiling (a legal cap to how much the US can borrow) by $480 billion, an action the House is expected to take too. That money will enable the US government to cover its loan obligations until early December, when Congress will once again have to either pass a longer-term increase or another stopgap suspension.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="4yKvro">
The current agreement is the product of a weekslong stalemate on the issue that saw Democrats trying to pressure the GOP into giving up their roadblock of an increase or suspension of the debt ceiling, and Republicans repeatedly refusing to do so.
</p>
<aside id="3UsDFv">
<div>
</div>
</aside>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="9ZQHQg">
The impasse had high stakes, as the US faced a rapidly approaching default deadline. According to Treasury Secretary Janet Yellen, the US could run out of money as early as October 18. Passing that deadline without an increase or suspension would have likely triggered a massive domestic and international economic collapse.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="o95Cu2">
Ultimately, Republican senators decided to cooperate with Democrats, for now. However, in approving this short-term fix, lawmakers have failed to address the issues that brought them to a stalemate in the first place. They’ve now set themselves up for another dangerous impasse when this bill expires after December 3.
</p>
<h3 id="hy7lzi">
The standoff, briefly explained
</h3>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="DF17cg">
Republicans have been intent on using the debt ceiling to make Democrats look bad.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="SXCWwv">
Prior to their offer to back an increase this week, Republicans had not only said that they wouldn’t vote for a suspension but also that they would be blocking Democrats’ attempts to approve one using regular legislative order. If Republicans didn’t previously block the vote, Democrats would have been able to pass it with 51 votes — but because they did, the measure required 60 to advance.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="SYzJeZ">
Instead, Republicans pushed Democrats to use budget reconciliation — another process that would enable them to raise the debt limit with just 51 votes — to increase the cap on their own. Democrats were reluctant to use budget reconciliation both because it can be a lengthy and convoluted process and because it would have required them to specify how much they are raising the debt limit (something they ended up having to do anyway for the December increase).
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="C4H29j">
Effectively, Republicans wanted Democrats on the record as having increased the debt limit by trillions of dollars in order to portray them during the midterms as big spenders. Additionally, Republicans argued that because Democrats are working on a partisan basis to pass an expansive social spending bill, they should take care of any debt ceiling increases on a partisan basis, too.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="TgKYKD">
“Republicans’ position is simple,” Senate Minority Leader Mitch McConnell wrote to President Joe Biden on Monday. “We have no list of demands. For two and a half months, we have simply warned that since your party wishes to govern alone, it must handle the debt limit alone as well.”
</p>
<figure class="e-image"></figure></li>
</ul>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><img alt=" " src="https://cdn.vox-cdn.com/thumbor/ETqmnsspz2pWdMjtxF7UuU6S4YA=/800x0/filters:no_upscale()/cdn.vox-
cdn.com/uploads/chorus_asset/file/22908680/GettyImages_1345371792.jpg"/> <cite>Win McNamee/Getty Images</cite></p>
<pre><code> &lt;figcaption&gt;Senate Majority Leader Chuck Schumer (D-NY) talks with reporters on October 7. The Senate voted to </code></pre>
increase the debt ceiling, enabling the US government to cover its loan obligations until early December.
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="5hivXi">
Democrats, on the other hand, have argued that Republicans ought to work with them to pass a suspension or increase, or simply get out of the way. One, because avoiding a gigantic economic collapse is in everyone’s interest, and the minority party hasn’t typically blocked action to this degree in the past. And two, because both Democrats and Republicans are responsible for the actual debt that this legislation would address.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="IMHhXo">
Both points are true: The debt grew nearly $8 trillion during the Trump administration as a result of massive tax cuts and pandemic relief. In that time frame, Republicans and Democrats both voted to suspend the debt limit three times. But that didn’t sway Republican lawmakers.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="c2WUfh">
Because Republicans had refused to give up their opposition and Democrats were intent on keeping the pressure on the GOP, the two sides were at an impasse until this week.
</p>
<h3 id="PXPi4n">
How the debt deal came together<strong> </strong>
</h3>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="pXTeCB">
On Wednesday, McConnell reversed his position and told Democrats that Republicans would not block a short-term increase to the debt limit into December.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="sX7MSC">
Adamant that they would not pursue reconciliation to raise the ceiling (and, given the deadline, likely out of time to try doing so) Democrats raised the possibility of creating a carve-out in the filibuster rules that would also allow them to pass debt ceiling measures with the 51 Democratic votes they have, rather than the 60 votes filibuster rules require.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="Ad0YVb">
That latter option appeared to be gaining momentum this week, although key moderates like Sen. Joe Manchin (D-WV) were still wary of it. As a sign of its traction, however, Biden — who has traditionally been cautious of altering filibuster rules — called carving out a special debt-ceiling- related exemption to the filibuster a “real possibility.”
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="RqH6OV">
That possibility may have spurred McConnell’s decision to cave for the time being. According to CNN’s Manu Raju, McConnell was worried about potential threats to the filibuster when he offered Democrats a deal to increase the debt ceiling for now.
</p>
<div id="BK3UGu">
<blockquote class="twitter-tweet">
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" dir="ltr" lang="en">
McConnell told his colleagues he’s concerned about pressure on Manchin and Sinema to gut filibuster in order to raise debt ceiling, I’m told. He pointed to this as reason why he is floating short-term increase in order to ease pressure on and push Democrats to use reconcilation
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">— Manu Raju (<span class="citation" data-cites="mkraju">@mkraju</span>) <a href="https://twitter.com/mkraju/status/1445816848801431561?ref_src=twsrc%5Etfw">October 6, 2021</a></p>
</blockquote>
</div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="bfGc5y">
The filibuster has allowed McConnell to block a range of Democratic priorities — from police to voting reforms — despite his party being in the minority. The assumption is that exempting the debt ceiling from the filibuster would increase pressure on Democrats to do so for other issues Republicans oppose, like expanding protections for voting rights.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="Pl7rxf">
For now, the filibuster stands. And the GOP’s move helps prevent the US from going into default in the near term. It does little to resolve the central conflict at hand, however. Republicans are still insisting, after all, that Democrats use budget reconciliation to approve a longer-term debt ceiling increase on a partisan basis.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="4nCTdH">
Democrats, meanwhile, are refusing to do so and may consider a filibuster carve-out again in December. “We’re not doing it on reconciliation,” Sen. Tim Kaine (D-VA) emphasized earlier this week.
</p>
<h3 id="vZSdR4">
There will be more debt drama in December
</h3>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="rATpDK">
The use of the debt limit as political leverage is nothing new.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="a3DTh5">
As Republicans have been fond of pointing out, Biden was among the Democratic senators who voted against raising it in 2006 in order to send a message about his disagreement with Republican policies. In that scenario, though, Democrats did not filibuster the legislation or prevent Republicans from approving it with a simple majority. Additionally, Republicans have previously withheld votes for debt ceiling increases in exchange for policy concessions, something that’s not the case this time around.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="0EfEG3">
This year, as Republicans emphasized, they took issue with the debt limit in order to simply make a point, a tough position to negotiate with.
</p>
<figure class="e-image">
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><img alt=" " src="https://cdn.vox-
cdn.com/thumbor/rd4T56sOZYOKhtO9tDhaWpNczsM=/800x0/filters:no_upscale()/cdn.vox-
cdn.com/uploads/chorus_asset/file/22908682/GettyImages_1235752503.jpg"/> <cite>Bloomberg via Getty Images</cite></p>
<figcaption>
Senator Elizabeth Warren (D-MA) speaks to reporters as the Senate was nearing a deal on a short-term increase to the debt ceiling.
</figcaption>
</figure>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="eNhznY">
This short-term fix does help Democrats in that it allows them to focus their time and energies instead on a larger social spending bill they’ve struggled to complete.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="oi1RHo">
“McConnell caved,” Sen. Elizabeth Warren (D-MA) told reporters. “And now we’re going to spend our time doing child care, health care, and fighting climate change.”
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="wyP2rV">
But the larger disagreements between Republicans and Democrats regarding how to move forward remain.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="TgKrsW">
And by procrastinating on solving them, lawmakers have set themselves up for a difficult December. The new deadline to address the debt ceiling also coincides with another deadline to pass more government appropriations — that is, the money needed to keep the government functioning.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="DDE7fe">
That means Congress will find itself in a tough spot yet again in just a few months. Not only will lawmakers have to solve their debt ceiling disagreements and stave off economic disaster, but they’ll have to do so while fighting over how to avoid a government shutdown.
</p>
<h1 data-aos="fade-right" id="from-the-hindu-sports">From The Hindu: Sports</h1>
<ul>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Olympic champion Neeraj Chopra wants to continue with current coach in 2024 Games as well</strong> - During a panel discussion at the ‘India Today Conclave’, Chopra said that Bartonietz’s methods suit him as the bio- mechanical expert cracks jokes even during intense sessions making training thoroughly enjoyable.</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>FIFA plans to postpone Club World Cup until 2022</strong> - FIFA is now exploring staging the event in January or February.</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>PCB can collapse if India wants as ICC is getting 90% of its funds from there: Ramiz Raja</strong> - Mr. Ramiz, in a candid briefing to the Senators, also said he would unveil his plans for Pakistan cricket and the board in a week or 10 days’ time</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Jemimah thanks The Hundred for her comeback</strong> - She became youngest to reach 1,000 runs in T20I Before rain intervened</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Meet Anuradha Doddaballapur, a cardiovascular scientist from Bengaluru and Germany’s cricket captain</strong> - Anuradha is also the first woman to pick up four consecutive wickets in T20 Internationals</p></li>
</ul>
<h1 data-aos="fade-right" id="from-the-hindu-national-news">From The Hindu: National News</h1>
<ul>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Mamata inaugurates big-ticket Durga puja pandals, asks people to abide by COVID protocols</strong> - The CM had on Wednesday, on the occasion of Mahalaya, inaugurated Naktala Udayan Sangha in south Kolkata.</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Punjab will be free from stubble burning if AAP comes to power: Delhi Environment Minister</strong> - Gopal Rai said Delhi has provided a solution to the problem of stubble burning with the Pusa bio-decomposer and it will be distributed for free in all Punjab districts like the AAP government has been doing</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Data | Which major Indian cities exceed WHO’s revised pollution limits?</strong> - As many as 95.6 deaths per one lakh people were recorded in India due to PM2.5 exposure in 2019</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>YSRCP leader seeks probe into ‘land grabbing’ activities of former MLA</strong> - ‘Kuna Ravikumar illegally transported sand worth ₹100 crore’</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>CCTV cameras to be installed at schools, medical shops in Kollam</strong> - Initiative’s aim is to curb substance abuse and child trafficking</p></li>
</ul>
<h1 data-aos="fade-right" id="from-bbc-europe">From BBC: Europe</h1>
<ul>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Nobel Peace Prize: Journalists Maria Ressa and Dmitry Muratov share award</strong> - The high-profile Philippine and Russian editors face threats and intimidation for doing their jobs.</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>COP26: Pope will not travel to Glasgow for climate summit</strong> - The Vatican confirms that Pope Francis will not attend the UN climate conference COP26.</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Samsung apologises for Russian app download error</strong> - The firm said a message sent to UK users saying Russian software had been installed was a mistake.</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>German elections: Defeated Merkel heir Laschet prepared to resign</strong> - Armin Laschet has called a conservative party congress next week for new leaders to be decided.</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Mica: Large crowd attends Mica redress protest march</strong> - Homeowners hit by the affect of mica are marching from the Garden of Remembrance to Custom House.</p></li>
</ul>
<h1 data-aos="fade-right" id="from-ars-technica">From Ars Technica</h1>
<ul>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Rocket Report: Falcon Heavy delayed due payload issue, DART gets a date</strong> - Also, an update on Arca’s first orbital launch attempt. - <a href="https://arstechnica.com/?p=1802188">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>No, your antibodies are not better than vaccination: An explainer</strong> - Infection does offer some immune protection—but it’s unreliable compared with vaccines. - <a href="https://arstechnica.com/?p=1802249">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Resident Evil reboot trailer looks like a welcome return to gaming roots</strong> - Director Johannes Roberts wanted to evoke dark tone and scary aspects of the games. - <a href="https://arstechnica.com/?p=1802183">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>iPadOS 15 mini-review: It’s all about the home screen</strong> - As an addendum to our iOS 15 review, we look at what’s new on the iPad. - <a href="https://arstechnica.com/?p=1802043">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Lunar samples returned by Chang’e-5 tell of recent volcanism</strong> - “Recent” is relative—the samples are roughly two billion years old. - <a href="https://arstechnica.com/?p=1802125">link</a></p></li>
</ul>
<h1 data-aos="fade-right" id="from-jokes-subreddit">From Jokes Subreddit</h1>
<ul>
<li><strong>Asked a Chick, “If I washed my dick would you….</strong> - <!-- SC_OFF -->
<div class="md">
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Asked a chick:
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
If I washed my dick would you suck it?
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Her: “Um, Wtf?” “No!”
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Me: “You dirty cocksucker!”
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
She laughed so much she eventually sucked me off as a gesture of appreciation of the joke. My sister is weird.
</p>
</div>
<!-- SC_ON -->
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"> submitted by <a href="https://www.reddit.com/user/NotSoFunny_FunnyGuy"> /u/NotSoFunny_FunnyGuy </a> <br/> <span><a href="https://www.reddit.com/r/Jokes/comments/q3n792/asked_a_chick_if_i_washed_my_dick_would_you/">[link]</a></span> <span><a href="https://www.reddit.com/r/Jokes/comments/q3n792/asked_a_chick_if_i_washed_my_dick_would_you/">[comments]</a></span></p></li>
<li><strong>3 guys are sitting around a campfire</strong> - <!-- SC_OFF -->
<div class="md">
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
One guy says to the other 2, “I’m the toughest guy here. One time I was out in the woods and I got attacked by a mountain lion! I wrestled with it and was able to stab it to death.” One of the other guys says, “You think that’s tough? I was out in the woods and got attacked by a full size grizzly bear. I wrestled with it and stuck my arm down it’s throat and strangled it to death!” The last guy just sat there poking the fire with his dick.
</p>
</div>
<!-- SC_ON -->
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"> submitted by <a href="https://www.reddit.com/user/icecreamandbutter"> /u/icecreamandbutter </a> <br/> <span><a href="https://www.reddit.com/r/Jokes/comments/q3i1gb/3_guys_are_sitting_around_a_campfire/">[link]</a></span> <span><a href="https://www.reddit.com/r/Jokes/comments/q3i1gb/3_guys_are_sitting_around_a_campfire/">[comments]</a></span></p></li>
<li><strong>I got fired from my job because I kept asking my customers whether they would prefer “Smoking” or “Non-smoking”.</strong> - <!-- SC_OFF -->
<div class="md">
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Apparently the correct terms are “Cremation” and “Burial”.
</p>
</div>
<!-- SC_ON -->
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"> submitted by <a href="https://www.reddit.com/user/lspatricio"> /u/lspatricio </a> <br/> <span><a href="https://www.reddit.com/r/Jokes/comments/q3dmol/i_got_fired_from_my_job_because_i_kept_asking_my/">[link]</a></span> <span><a href="https://www.reddit.com/r/Jokes/comments/q3dmol/i_got_fired_from_my_job_because_i_kept_asking_my/">[comments]</a></span></p></li>
<li><strong>A Chicken Goes to a Fox for Therapy</strong> - <!-- SC_OFF -->
<div class="md">
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
A chicken, Sergio Cortez, goes to his therapist , a fox named Francisco Arroyo. Francisco has a tweed jacket with elbow patches. Sergio, the chicken, says to him "Dr. I want to end my life. I want to shoot myself in the head and commit suicide.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
The therapist responds “Sergio, tell my about how you are feeling and why you are feeling this way. Sergio says”When I was a young chick, I was abused by a relative. My parents did not believe me. Then, my older brother Jesus Cortez, was killed horrifically in a farming accident. He was shredded into chicken fingers right before my eyes. My parents blamed me for his death and wished I had died instead.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
The therapist says " That’s horrible, you must feel so much trauma. Let’s talk about it before you do anything." Sergio interrupts “You don’t understand, my parents and I reconciled some years back. We have a great relationship now and I no longer feel sad about my brother’s death. But when I was 18 I signed up for the military and was sent far away from home. I did horrible things, slaughtered women and children. I still see their faces sometimes.” The therapist responds “I see, many veterans of war suffer from depression, especially if you did something that compromised your morals so deeply.” Sergio replies “Doc, I’ve never told anyone this, but I enjoyed it! People, deep down, are basically animals I believe. I was like a blood thirsty wolf and when I see the faces of my victims I smile. But after the war I became so lonely. I no longer had my war buddies and I’ve always been an ugly duckling so no woman wanted to have sex with me.” The therapists nods and says " I see, loneliness can be very very hard on a person, but i can help you with strategies to make friends, your lonliness is only temporary and suicide is permanent." Sergio interrupts “Doc its OK now. After a couple years of bumming around I got a good paying job and found a woman who appreciated what I can provide for her. I have 5 daughters and 5 sons and I haven’t felt lonely in years. Really, I’m doing great!”
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
The therapist, puzzled, asks" I don’t understand, if you are feeling so amazing why are you wanting to commit suicide?"
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
The chicken replies " To get to the <em>other side</em>."
</p>
</div>
<!-- SC_ON -->
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"> submitted by <a href="https://www.reddit.com/user/Mobely"> /u/Mobely </a> <br/> <span><a href="https://www.reddit.com/r/Jokes/comments/q38gyc/a_chicken_goes_to_a_fox_for_therapy/">[link]</a></span> <span><a href="https://www.reddit.com/r/Jokes/comments/q38gyc/a_chicken_goes_to_a_fox_for_therapy/">[comments]</a></span></p></li>
<li><strong>How many guitarists does it take to play Wonderwall?</strong> - <!-- SC_OFF -->
<div class="md">
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Apparently, all of them.
</p>
</div>
<!-- SC_ON -->
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"> submitted by <a href="https://www.reddit.com/user/theuniversaltool"> /u/theuniversaltool </a> <br/> <span><a href="https://www.reddit.com/r/Jokes/comments/q3foer/how_many_guitarists_does_it_take_to_play/">[link]</a></span> <span><a href="https://www.reddit.com/r/Jokes/comments/q3foer/how_many_guitarists_does_it_take_to_play/">[comments]</a></span></p></li>
</ul>
<script>AOS.init();</script></body></html>

4
index.html
View File

File diff suppressed because one or more lines are too long